If you're reading this in 2026, here's an experiment to try right now. Open ChatGPT. Ask it: "What are the most innovative companies working on [your therapeutic area or technology]?"
Look at the answer. Are you on the list? If you're not, you have a problem. If your competitors are and you're not, you have a bigger problem. And if the answer is wrong about you specifically — describing you incorrectly, or attributing your work to a competitor — you have the biggest problem of all.
This is the biotech AI search visibility crisis. Most biotech companies don't know it's happening. The ones that figure it out first are going to dominate their categories for the next decade.
What's actually changing
Buyer behavior in biotech has quietly shifted. A growing percentage of investor research, BD scoping, and competitive analysis now begins not in Google — but in ChatGPT, Perplexity, Claude, or Google's AI Overviews.
The numbers from analyst reports tell the story. Search engine traffic to traditional sites is declining as AI assistants absorb queries. Click-through rates on Google have collapsed where AI Overviews appear. And the brands that AI models cite consistently are not always the brands that dominate traditional Google search.
This means: you can be ranking #1 on Google for your category and still be invisible to the majority of buyers in 2026 — because they're not on Google anymore.
How AI models actually decide what to cite
This is the part most marketers get wrong. AI models don't cite based on traditional SEO signals. They cite based on a different set of factors:
- Entity recognition. Does the model know what your company is, what category it operates in, and how it relates to other entities?
- Source diversity. Are you mentioned across multiple authoritative sources — Wikipedia, scientific databases, news coverage, industry analysis?
- Semantic clarity. Is your content structured in a way that's easy for the model to extract and quote?
- Recency and consistency. Do recent sources reinforce older sources about who you are and what you do?
Notice what's missing: backlink count, domain authority, on-page keyword density. Most of the SEO industry has spent two decades optimizing for things that don't matter to AI search at all.
The biotech-specific opportunity
Here's what makes this an unusually attractive moment for biotech: almost no biotech is doing this. Even the biggest pharma companies are still treating their digital presence like it's 2018. The big SEO agencies don't understand biotech vocabulary. The biotech marketing agencies don't understand AI search.
This is one of those rare windows where a deliberate, intelligent investment now produces a position that's difficult to displace later. The biotechs that engineer their AI search visibility in 2026 will be the default citations for their category in 2028 — and citations compound.
The biotech that becomes ChatGPT's default answer for "best companies working on [your category]" will receive a flow of warm investor and partner inquiries that no SEO investment can replicate.
What actually moves the needle (concrete tactics)
1. Brand entity engineering
Make sure your company exists clearly in the structured data sources AI models train on. This means proper Wikipedia presence (where it's appropriate and earned), Wikidata entries, Crunchbase profiles, scientific database citations, and consistent representation across knowledge graphs.
2. AI-readable content reformatting
Your existing content is probably structured for human readers, not for AI extraction. Reformatting key pages with clear definitional statements, structured FAQs, and explicit entity relationships dramatically improves citation likelihood.
3. llm.txt and structured signals
The web's emerging standards for AI-discoverability — llm.txt, schema.org enrichment, semantic HTML — give you a way to actively communicate with AI crawlers about who you are and what you do. Almost no biotech does this yet.
4. Authoritative third-party coverage
AI models trust diversity of sources. A single mention on your own website is weak. Mentions across industry publications, scientific reviews, podcast transcripts, and analyst reports compound to lock in your position.
5. Consistent prompt-level monitoring
You can't optimize what you don't measure. We track how 50+ "golden prompts" are answered by major AI models monthly for our clients — and adjust strategy based on actual model behavior, not theory.
What happens if you wait
The window closes. Once an AI model has reliably cited a competitor as the answer to "best company working on X," it becomes structurally hard to displace them — because every future training cycle reinforces the existing pattern.
This is the inverse of the SEO timing many biotechs missed in 2010-2015. The companies that invested in serious SEO when their competitors thought it was unnecessary spent the next decade collecting compounding traffic. The same dynamic is now playing out in AI search — but compressed into a much shorter window.
The biotechs that move now will be the AI-default for their categories for years. The biotechs that wait will spend the rest of the decade trying to claw back ground that's already been ceded.